AN2治疗公司与GSK达成合作，共同推进基于硼的结核病治疗方法的发展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis

动脉网11-11

AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).AN2 Therapeutics与GSK达成了一项研究合作，以开发治疗结核病（TB）的新疗法。The Gates Foundation will provide an ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582936115?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-11 14:19","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2582936115","market":"us","top_or_hot":-1,"title":"AN2治疗公司与GSK达成合作，共同推进基于硼的结核病治疗方法的发展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis","media":"动脉网","content":"<div>\n<p>AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).AN2 Therapeutics与GSK达成了一项研究合作，以开发治疗结核病（TB）的新疗法。The Gates Foundation will provide an ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AN2治疗公司与GSK达成合作，共同推进基于硼的结核病治疗方法的发展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAN2治疗公司与GSK达成合作，共同推进基于硼的结核病治疗方法的发展AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-11 14:19 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b><strong>动脉网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).AN2 Therapeutics与GSK达成了一项研究合作，以开发治疗结核病（TB）的新疗法。The Gates Foundation will provide an ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b","article_id":"2582936115","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111114212194fcffac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582936115","pubTimestamp":1762841940,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis .AN2 Therapeutics与GSK达成了一项研究合作，以开发治疗结核病的新疗法。经验证的LeuRS靶点是多种化合物的基础，包括用于治疗NTM肺病的在研药物epetraborole、用于治疗结核病的在研药物ganfeborole，以及获得FDA批准的抗真菌药物tavaborole。This collaboration builds on previous work between AN2’s team and GSK’s Global Health research and development group. It represents a joint effort to explore innovative approaches that could help address the growing burden of TB, particularly in low-income countries.这项合作建立在AN2团队与GSK全球健康研发小组之前的工作基础之上。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","ANTX":"AN2 Therapeutics, Inc.","LENZ":"Therapeutics","BK4588":"碎股","BK4539":"次新股","GSK":"葛兰素史克","BK4585":"ETF&股票定投概念","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","GSK.UK":"葛兰素史克"},"translate_title":"AN2 Therapeutics and GSK reach a partnership to jointly advance the development of boron-based tuberculosis treatments AN2 Therapeutics Enters into Collaboration with GSK to Advance Boronased Therapies for Tuberculosis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANTX":0.9,"GSK":1.5,"LENZ":1.5,"GSK.UK":0.6},"content_text":"AN2 Therapeutics has entered into a research collaboration with GSK to develop new treatments for tuberculosis (TB).AN2 Therapeutics与GSK达成了一项研究合作，以开发治疗结核病（TB）的新疗法。The Gates Foundation will provide an additional year of funding to support AN2’s work within this partnership.盖茨基金会将提供额外一年的资金，以支持 AN2 在此合作伙伴关系中的工作。Tuberculosis remains one of the world’s most severe health challenges, affecting over a quarter of the global population and causing more than 1.25 million deaths each year. The collaboration aims to develop boron-based leucyl-tRNA synthetase (LeuRS) inhibitors, a new class of compounds targeting novel mechanisms not accessible through conventional carbon-based chemistry..结核病仍然是全球最严峻的健康挑战之一，影响着全球超过四分之一的人口，每年导致超过125万人死亡。此次合作旨在开发基于硼的亮氨酰-tRNA合成酶（LeuRS）抑制剂，这是一类针对传统碳基化学无法触及的新机制的新型化合物。AN2’s boron chemistry platform has shown potential in developing drugs for infectious diseases such as nontuberculous mycobacterial (NTM) lung disease and TB. The same validated LeuRS target forms the basis of several compounds, including epetraborole (in development for NTM lung disease), ganfeborole (in development for TB), and tavaborole, an FDA-approved antifungal..AN2的硼化学平台在开发治疗传染病（如非结核分枝杆菌（NTM）肺病和结核病）药物方面显示出潜力。经验证的LeuRS靶点是多种化合物的基础，包括用于治疗NTM肺病的在研药物epetraborole、用于治疗结核病的在研药物ganfeborole，以及获得FDA批准的抗真菌药物tavaborole。This collaboration builds on previous work between AN2’s team and GSK’s Global Health research and development group. It represents a joint effort to explore innovative approaches that could help address the growing burden of TB, particularly in low-income countries.这项合作建立在AN2团队与GSK全球健康研发小组之前的工作基础之上。它代表了一项共同努力，探索创新方法，可能有助于应对结核病日益加重的负担，特别是在低收入国家。By combining AN2’s expertise in boron-based drug discovery with GSK’s global health capabilities and continued support from the Gates Foundation, the initiative aims to contribute to the development of new and effective therapies for tuberculosis.通过结合AN2在硼基药物发现方面的专业知识与GSK的全球健康能力，以及盖茨基金会的持续支持，该计划旨在为结核病开发新的有效疗法做出贡献。Source: businesswire.com来源：businesswire.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582936115","isCrawlerRequest":true}